The Biopharmaceutical industry has been one of the most profitable industries last year. A number of companies have appreciated to sky high valuations and returned investors a lot of money. While this price appreciation is good news for investors that are already invested in a stock, it leaves little room for new investors to make money. There are still a few biopharmaceuticals available at cheap valuations, I believe Galena Biopharma Inc (NASDAQ:GALE) and Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) are two biopharmaceutical stocks which still offer a considerable upside to investors.
The share price of Oncolytics has appreciated by more than 45% in the last few months due to positive market perception of Reolysin. The Canadian company is involved in the development of cancer therapies. The primary drug of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) is Reolysin, which has undergone approximately 32 different trials for various forms of cancer; of those, 16 trials have been successfully completed. The drug has the ability to treat tumors which are RAS activated and according to studies approximately 67% of all cancers are RAS activated.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) has recently released data for the effect of Reolysin on Neck and Head cancer and Carcinoma of the lung. According to top line data, from trials on patients with head and neck cancer, the combination of Reolysin with paclitaxel and carboplatin had a higher likelihood of smaller tumors. The trials showed that the combination was 19% more effective than standard therapy. The mid-stage Phase II data from Reolysin’ SCCLC trials show that the combination of Reolysin and carboplatin & paclitaxel was able to reduce tumor size in 95% patients.
The patent cliff makes Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) an interesting acquisition target for large pharmaceuticals facing expiring patents. The wide oncology applications of Reolysin makes it gold for companies with strong oncology pipelines. The mean sell side target price on Oncolytics is $7.40, which is more than a 100% return on current price levels. I believe the company is both a strong acquisition target and has the potential to appreciate further on more trial data for Reolysin.